Open AccessA patient‐derived explant ( PDE ) model of hormone‐dependent cancer
Author(s) -
Centenera Margaret M.,
Hickey Theresa E.,
Jindal Shalini,
Ryan Natalie K.,
Ravindranathan Preethi,
Mohammed Hisham,
Robinson Jessica L.,
Schiewer Matthew J.,
Ma Shihong,
Kapur Payal,
Sutherland Peter D.,
Hoffmann Clive E.,
Roehrborn Claus G.,
Gomella Leonard G.,
Carroll Jason S.,
Birrell Stephen N.,
Knudsen Karen E.,
Raj Ganesh V.,
Butler Lisa M.,
Tilley Wayne D.
Publication year - 2018
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12354
Subject(s) - ex vivo , explant culture , in vivo , prostate cancer , prostate , personalized medicine , breast cancer , organoid , cancer research , drug discovery , computational biology , biology , cell culture , cancer , in vitro , medicine , oncology , bioinformatics , microbiology and biotechnology , biochemistry , genetics
Breast and prostate cancer research to date has largely been predicated on the use of cell lines in vitro or in vivo . These limitations have led to the development of more clinically relevant models, such as organoids or murine xenografts that utilize patient‐derived material; however, issues related to low take rate, long duration of establishment, and the associated costs constrain use of these models. This study demonstrates that ex vivo culture of freshly resected breast and prostate tumor specimens obtained from surgery, termed patient‐derived explants ( PDE s), provides a high‐throughput and cost‐effective model that retains the native tissue architecture, microenvironment, cell viability, and key oncogenic drivers. The PDE model provides a unique approach for direct evaluation of drug responses on an individual patient's tumor, which is amenable to analysis using contemporary genomic technologies. The ability to rapidly evaluate drug efficacy in patient‐derived material has high potential to facilitate implementation of personalized medicine approaches.